Statin Therapy For Patients With Cardiovascular Disease (SPC) Measure In HEDIS 2017 | Jane Jackson, RN, CRC | RxEconsult
Menus

All Health Articles

HEDIS 2017 Measure For Statin Therapy For Patients With Cardiovascular Disease (SPC) Category: Healthcare Administration by - December 22, 2016 | Views: 19836 | Likes: 0 | Comment: 0  

The following rates are reported for Statin Therapy for Patients with Cardiovascular Disease

Rate 1—Received Statin Therapy

The number of members who had at least one dispensing event for a high or moderate-intensity statin medication during the measurement year.

High-intensity Statin therapy   

  • Atorvastatin 40–80 mg
  • Amlodipine-atorvastatin 40-80 mg
  • Ezetimibe-atorvastatin 40-80 mg            
  • Rosuvastatin 20–40 mg
  • Simvastatin 80 mg
  • Ezetimibe-simvastatin 80 mg

Moderate-intensity Statin therapy        

  • Atorvastatin 10–20 mg
  • Amlodipine-atorvastatin 10-20 mg
  • Ezetimibe-atorvastatin 10-20 mg
  • Rosuvastatin 5–10 mg
  • Simvastatin 20–40 mg
  • Ezetimibe-simvastatin 20-40 mg
  • Niacin-simvastatin 20-40 mg
  • Sitagliptin-simvastatin 20-40 mg
  • Pravastatin 40–80 mg
  • Aspirin-pravastatin 40-80 mg
  • Lovastatin 40 mg
  • Niacin-lovastatin 40 mg
  • Fluvastatin XL 80 mg
  • Fluvastatin 40 mg bid
  • Pitavastatin 2–4 mg

Note: Please review NCQA HEDIS 2017, Volume 2 for a comprehensive list of medications and NDC codes related to this measure.  www.ncqa.org.

Rate 2 – Statin Adherence 80%

  • The number of members who achieved a PDC (Proportion of Days Covered) of at least 80% during the treatment period.
  • Report two age/gender categories and a total rate.
  • Males 21–75 years as of December 31 of the measurement year.
  • Females 40–75 years as of December 31 of the measurement year.
  • Total.
Continue


For More Healthcare Insights Join Us On Twitter
and Facebook. Join The Community To Publish Articles.

Copyright 2019 RxEconsult. All Rights Reserved | Privacy Policy | Terms of Use | Sitemap